{
 "name": "太景*-KY",
 "slug": "tw-4157",
 "aliases": [
  "太景醫藥研發控股股份有限公司",
  "TAIGEN",
  "4157"
 ],
 "ticker": "4157",
 "industry": "生技醫療業",
 "website": "http://www.taigenbiotech.com/",
 "summary": "太景*-KY（4157）是上櫃的生技醫療類股公司，2005 年成立，2014 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "太景醫藥研發控股股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "TAIGEN",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2014-01-17",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2005-09-15",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "黃國龍",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "張俐雯",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 20766551,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "http://www.taigenbiotech.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 3150,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 212.81,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 12.27,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of均一致並保留。出表日1151017；僅更正source及補此note。"
  },
  {
   "claim": "管線：TG-873870（太捷信／nemonoxacin）",
   "value": "社區型肺炎｜口服膠囊及靜脈輸液 NDA 已獲受理審查｜越南",
   "unit": "",
   "as_of": "2026-10-18",
   "source": "https://www.taigenbiotech.com/tw/news/detail/227"
  },
  {
   "claim": "管線：TG-873870（太捷信／nemonoxacin）",
   "value": "社區型肺炎｜已取得上市許可｜台灣、中國、俄羅斯",
   "unit": "",
   "as_of": "2025-10-01",
   "source": "https://www.taigenbiotech.com/tw/news/detail/210"
  },
  {
   "claim": "管線：TG-1000（Pixavir marboxil）",
   "value": "成人及12歲以上青少年之單純性A型及B型流感｜口服膠囊已獲 NMPA 上市核准｜中國",
   "unit": "",
   "as_of": "2025-12-11",
   "source": "https://www.taigenbiotech.com/tw/news/detail/219"
  },
  {
   "claim": "管線：TG-1000（Pixavir marboxil／BRC-201）",
   "value": "成人及青少年急性無併發症流感｜III期臨床試驗 IND 已核准｜南韓",
   "unit": "",
   "as_of": "2026-08-10",
   "source": "https://www.taigenbiotech.com/tw/news/detail/226"
  },
  {
   "claim": "管線：ISM-4808（HIF-PHD抑制劑）",
   "value": "慢性腎臟病貧血｜I期臨床已啟動並完成首例給藥｜試驗地區未公開",
   "unit": "",
   "as_of": "2026-03-03",
   "source": "https://www.taigenbiotech.com/tw/news/detail/224",
   "note": "NCT 編號：NCT07415304；臨床I期先於健康受試者進行；該登錄未列試驗地點，公告亦未明列本次I期地區；不將2023中國IND許可等同本次試驗地點。"
  },
  {
   "claim": "管線：TG-4318（DPP1抑制劑）",
   "value": "支氣管擴張症｜臨床前候選藥物評估，準備進入臨床前試驗｜中國、香港、澳門",
   "unit": "",
   "as_of": "2025-12-01",
   "source": "https://www.taigenbiotech.com/tw/news/detail/217",
   "note": "地區為該授權合作負責之開發地區，不表示其他地區已開展試驗。"
  },
  {
   "claim": "管線：TG-2349（furaprevir）",
   "value": "基因型1型C型肝炎（合併DAG181及ribavirin）｜III 期（已完成）｜中國",
   "unit": "",
   "as_of": "2021-02-04",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04155515",
   "note": "NCT 編號：NCT04155515；as_of 為登錄最後更新公開日。歷史試驗登錄；不代表2026仍持有全部權利或已取得上市許可。"
  },
  {
   "claim": "授權合作：TG-1000",
   "value": "健康元藥業集團股份有限公司｜中國、香港、澳門（不含台灣）｜2023-03-21",
   "unit": "",
   "as_of": "2023-03-22",
   "source": "https://www.taigenbiotech.com/tw/material/detail/62",
   "note": "官網重大訊息轉載：發布2023-03-22，事實發生日2023-03-21；保留原始契約日期，未用隔日新聞日期。"
  },
  {
   "claim": "簽約金：TG-1000（健康元交易）",
   "value": 20000000,
   "unit": "人民幣",
   "as_of": "2023-03-22",
   "source": "https://www.taigenbiotech.com/tw/material/detail/62",
   "note": "公告稱合約生效後支付；不是已收款證據。"
  },
  {
   "claim": "權利金比率：TG-1000（健康元交易）",
   "value": "不超過11%",
   "unit": "%",
   "as_of": "2023-03-22",
   "source": "https://www.taigenbiotech.com/tw/material/detail/62",
   "note": "原文「不超過11%之銷售權利金」；為比率上限，不是固定11%。"
  },
  {
   "claim": "授權合作：TG-1000",
   "value": "Boryung Biopharma｜南韓｜2026-01-26",
   "unit": "",
   "as_of": "2026-01-26",
   "source": "https://www.taigenbiotech.com/tw/material/detail/181",
   "note": "官網重大訊息標題明示1月26日董事會通過並完成簽署，事實發生日115/01/26；1月28日另舉行儀式，不以儀式日覆寫原簽約事件日。"
  },
  {
   "claim": "授權合作：TG-4318",
   "value": "健康元藥業集團股份有限公司｜中國、香港、澳門（不含台灣）｜2025-12-01",
   "unit": "",
   "as_of": "2025-12-01",
   "source": "https://www.taigenbiotech.com/tw/material/detail/175"
  },
  {
   "claim": "授權合作：ISM-4808",
   "value": "英矽智能科技（上海）有限公司及 Insilico Medicine IP Limited｜中國、香港、澳門、台灣｜2025-12-12",
   "unit": "",
   "as_of": "2025-12-12",
   "source": "https://www.taigenbiotech.com/tw/material/detail/180",
   "note": "此筆為太景引進授權，非太景授出或已收款；簽署授權協議之事實發生日114/12/12。"
  },
  {
   "claim": "授權合作：TG-873870",
   "value": "Fideschem Inc.、Newsun Pharmaceutical JSC.｜越南｜2025-10-01",
   "unit": "",
   "as_of": "2025-10-01",
   "source": "https://www.taigenbiotech.com/tw/material/detail/164",
   "note": "簽署三方授權協議之事實發生日114/10/01；非契約起日推算。"
  },
  {
   "claim": "授權合作：TG-0054",
   "value": "GPCR Therapeutics Inc.｜全球（權利轉讓）｜2020-11-09",
   "unit": "",
   "as_of": "2020-11-09",
   "source": "https://www.taigenbiotech.com/tw/news/detail/151",
   "note": "全球權利轉讓，非仍由太景自主推進的現行資產；此筆記歷史交易。"
  },
  {
   "claim": "授權合作：TG-873870",
   "value": "GPCR Therapeutics Inc.｜南韓｜2020-11-09",
   "unit": "",
   "as_of": "2020-11-09",
   "source": "https://www.taigenbiotech.com/tw/news/detail/151"
  },
  {
   "claim": "催化劑：ISM-4808",
   "value": "試驗登錄預估主要完成日｜2026-11-30（登錄預估）｜已公告",
   "unit": "",
   "as_of": "2026-02-17",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07415304",
   "note": "NCT 編號：NCT07415304；登錄之 ESTIMATED 日期，不是結果公布日或已完成證據；as_of 為 lastUpdatePostDate。"
  },
  {
   "claim": "授權合作：TG-1000",
   "value": "某印度國際級製藥公司（名稱未公開）｜印度｜2025-10-23",
   "unit": "",
   "as_of": "2025-10-23",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢4157、114年度、全年度、序號1。發言日期2025-10-23 14:34:07；主旨：代子公司太景生物科技股份有限公司公告與某印度國際級製藥公司簽署「授權協議」。官方簽署事件事實發生日為114/10/23，據此記錄簽署日期；不是單以官網發稿日推定。範圍為印度開發、製造、藥證申請與市場銷售；簽約金、里程碑與權利金數值未公開。"
  },
  {
   "claim": "管線：TG-1000（Pixavir marboxil小兒劑型）",
   "value": "未滿12歲兒童之急性流感病毒感染｜小兒劑型III期臨床試驗已獲准｜中國",
   "unit": "",
   "as_of": "2025-10-26",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢4157、114年度、全年度、序號1。發言日期2025-10-26 21:32:41；主旨：公告本公司接獲合作夥伴健康元藥業集團通知抗流感病毒新藥Pixavir marboxil (TG-1000)獲中國大陸國家藥品監督管理局（NMPA）同意進行小兒劑型三期臨床試驗。事實發生日2025-10-23；CDE同意開展小兒III期，並非小兒適應症上市核准。NCT查無。"
  },
  {
   "claim": "催化劑：TG-1000小兒劑型",
   "value": "小兒劑型III期臨床試驗完成｜2026（公司預估）｜已公告",
   "unit": "",
   "as_of": "2025-10-26",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢4157、114年度、全年度、序號1。發言日期2025-10-26 21:32:41；主旨：公告本公司接獲合作夥伴健康元藥業集團通知抗流感病毒新藥Pixavir marboxil (TG-1000)獲中國大陸國家藥品監督管理局（NMPA）同意進行小兒劑型三期臨床試驗。第6項下一階段預計於2026年完成，未給季度或月份；保留原公告年份，不補日期。這是2025公告之預估，尚無較新完成或延後證據，不代表現行排程已再確認或已有試驗結果。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-4157.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}